ASLAN Pharmaceuticals
0
0
+€0.00+0% 00:00 今天
統計
當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-
競爭對手
此清單為基於近期市場事件的分析。並非投資建議。
關於
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Show more...
執行長
員工
35
國家
美國
ISIN
US04522R1014
WKN
000A3D7BB
上市
0 Comments
分享你的想法
FAQ
ASLAN Pharmaceuticals 的股票代號是什麼？▼
根據交易所不同，股票代號可能會有所差異。例如，在 Boerse Muenchen 交易所，ASLAN Pharmaceuticals 的股票以代號 7A9.MU 進行交易。
ASLAN Pharmaceuticals 有多少名員工？▼
截至 September 05, 2026，公司共有 35 名員工。
ASLAN Pharmaceuticals 位於哪個產業？▼
ASLAN Pharmaceuticals從事於Technology產業。
ASLAN Pharmaceuticals 何時完成拆股？▼
ASLAN Pharmaceuticals 最近沒有進行任何拆股。
ASLAN Pharmaceuticals 的總部在哪裡？▼
ASLAN Pharmaceuticals 的總部位於 美國 的 190 Elgin Avenue。